<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2018.7870</article-id>
<article-id pub-id-type="publisher-id">OL-0-0-7870</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Bin</given-names></name>
<xref rid="af1-ol-0-0-7870" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Qian</surname><given-names>Feng</given-names></name>
<xref rid="af2-ol-0-0-7870" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Wenjia</given-names></name>
<xref rid="af1-ol-0-0-7870" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Yang</given-names></name>
<xref rid="af1-ol-0-0-7870" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Han</surname><given-names>Yangdong</given-names></name>
<xref rid="af2-ol-0-0-7870" ref-type="aff">2</xref>
<xref rid="c1-ol-0-0-7870" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-0-0-7870"><label>1</label>Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China</aff>
<aff id="af2-ol-0-0-7870"><label>2</label>Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-0-0-7870"><italic>Correspondence to</italic>: Dr Yangdong Han, Department of Anesthesiology, China-Japan Union Hospital of Jilin University, 126 Sendai Street, Changchun, Jilin 130033, P.R. China, E-mail: <email>hydsubmission@163.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>04</month>
<year>2018</year></pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>01</month>
<year>2018</year></pub-date>
<volume>15</volume>
<issue>4</issue>
<fpage>4662</fpage>
<lpage>4668</lpage>
<history>
<date date-type="received"><day>24</day><month>05</month><year>2016</year></date>
<date date-type="accepted"><day>10</day><month>11</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018, Spandidos Publications</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<abstract>
<p>The present study aimed to assess whether different anesthesia methods (general anesthesia and general anesthesia combined with epidural block) were associated with tumor metastasis during the perioperative period and the possible molecular mechanisms of tumor metastasis. A rat hepatoma tumor xenograft model was constructed via the subcutaneous injection of Morris hepatoma 3924A cells into the upper axillary fossa. General anesthesia and general anesthesia combined with epidural block prior to hepatectomy were conducted on tumor-bearing rats. The average numbers of metastatic nodules on the lung surface were calculated in the different groups and the presence of abdominal lymph node metastases, rate of malignant ascites and abdominal wall-implanted nodules were recorded. Blood samples were collected from the orbits of rats immediately prior to surgery and at 2, 7 and 30 days following surgery. Plasma levels of interferon-&#x03B3;, transforming growth factor-&#x03B1; and vascular endothelial growth factor (VEGF) were measured. Finally, the expression of phosphorylated signal transducer and activator of transcription-3 and phosphorylated VEGF were measured by western blot analysis. The results of this analysis demonstrated that tumor metastasis was greatly suppressed when the rats underwent general anesthesia combined with epidural block prior to hepatectomy, compared with general anesthesia alone. The results of cytokine quantification and western blot analysis revealed that the anti-metastatic effect of general anesthesia combined with epidural block may have been mediated by inhibition of STAT3 and the relevant cytokines.</p>
</abstract>
<kwd-group>
<kwd>general anesthesia</kwd>
<kwd>general anesthesia combined with epidural block</kwd>
<kwd>signal transducer and activator of transcription 3</kwd>
<kwd>tumor metastasis</kwd>
<kwd>antitumor mechanism</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Primary liver cancer has the fifth-highest incidence of malignant tumors and is the third-leading cause of cancer-associated mortality, 90&#x0025; of cases are hepatocellular carcinoma (HCC) (<xref rid="b1-ol-0-0-7870" ref-type="bibr">1</xref>). In certain areas of Asia and the Middle East, HCC ranks as the leading cause of cancer-associated mortality (<xref rid="b2-ol-0-0-7870" ref-type="bibr">2</xref>). Surgical resection, which is the first-choice treatment modality for HCC, can significantly improve the prognosis and prolong the survival time of patients. However, surgery inevitably induces neuroendocrine, metabolic and inflammatory responses (<xref rid="b3-ol-0-0-7870" ref-type="bibr">3</xref>,<xref rid="b4-ol-0-0-7870" ref-type="bibr">4</xref>), directly affecting post-operative recovery and the survival time of patients (<xref rid="b5-ol-0-0-7870" ref-type="bibr">5</xref>,<xref rid="b6-ol-0-0-7870" ref-type="bibr">6</xref>). Consequently, the induction of this immune response can be injurious to long-term prognosis during the perioperative period. Therefore, the perioperative period is a critical period for long-term prognosis. The primary method of improving the long-term prognosis of tumor patients is to understand the mechanisms of tumor metastasis and corresponding immune responses. Recently, substantial attention has been paid to the association between methods of anesthesia and long-term prognosis (<xref rid="b7-ol-0-0-7870" ref-type="bibr">7</xref>). As an important role in the whole perioperative period, the responsibility of the anesthetists to improve the long-term prognosis of cancer patients has been increasingly appreciated in recent years (<xref rid="b8-ol-0-0-7870" ref-type="bibr">8</xref>). Metastasis is one of the most important characteristics of malignant tumors, serving an important role in treatment efficacy and quality of life of patients (<xref rid="b9-ol-0-0-7870" ref-type="bibr">9</xref>). The metastasis of tumors comprises of a complex series of events and can be divided into a number of sequential steps: i) Release from the primary tumor and invasion into the surrounding tissues; ii) intravasation; iii) transition in the blood circulation; iv) arrest in the capillary bed; v) extravasation; and vi) growth at preferred sites (<xref rid="b10-ol-0-0-7870" ref-type="bibr">10</xref>). In this cascade, angiogenesis, the formation of a new blood supply from pre-existing vasculature, is a critical step of tumor metastasis (<xref rid="b11-ol-0-0-7870" ref-type="bibr">11</xref>). Angiogenesis is a complex multistage process that is regulated by the balance between angiogenic and angiostatic factors (<xref rid="b12-ol-0-0-7870" ref-type="bibr">12</xref>&#x2013;<xref rid="b14-ol-0-0-7870" ref-type="bibr">14</xref>). Among these associated factors, vascular endothelial growth factor (VEGF) has been demonstrated to be one of the most important angiogenic mediators (<xref rid="b15-ol-0-0-7870" ref-type="bibr">15</xref>). VEGF is the most commonly studied angiogenic mediator and has been well established as a molecular target in clinical studies (<xref rid="b16-ol-0-0-7870" ref-type="bibr">16</xref>,<xref rid="b17-ol-0-0-7870" ref-type="bibr">17</xref>) In addition to its role in stimulating angiogenesis, VEGF induces vascular permeability to circulating macromolecules (<xref rid="b16-ol-0-0-7870" ref-type="bibr">16</xref>). Previous studies (<xref rid="b18-ol-0-0-7870" ref-type="bibr">18</xref>,<xref rid="b19-ol-0-0-7870" ref-type="bibr">19</xref>) have shown that signal transducer and activator of transcription 3 (STAT3) regulates angiogenesis primarily by modulating VEGF expression, although several other candidates affected by STAT3 have been reported to show distinct effects on angiogenesis.</p>
<p>General anesthesia (GA) and GA combined with epidural block (GEA) are the most commonly anesthetic methods in hepatectomy. GEA can prevent or attenuate the surgical stress response by blocking afferent neural transmission, which prevents harmful afferent input from reaching the central nervous system (<xref rid="b20-ol-0-0-7870" ref-type="bibr">20</xref>). Previous studies (<xref rid="b21-ol-0-0-7870" ref-type="bibr">21</xref>,<xref rid="b22-ol-0-0-7870" ref-type="bibr">22</xref>) have shown that the choice of anesthesia methods was only associated with perioperative stress and immune function for a short time. However, animal experiments and clinical studies (<xref rid="b23-ol-0-0-7870" ref-type="bibr">23</xref>,<xref rid="b24-ol-0-0-7870" ref-type="bibr">24</xref>) in recent years have reported that different anesthetic methods serve important roles in cancer recurrence or metastasis. Compared with GA, GEA significantly reduces the dependency on opioids (<xref rid="b25-ol-0-0-7870" ref-type="bibr">25</xref>). Opioids, including morphine, one of the most commonly used, can inhibit cellular and humoral immune function (<xref rid="b26-ol-0-0-7870" ref-type="bibr">26</xref>,<xref rid="b27-ol-0-0-7870" ref-type="bibr">27</xref>). An animal study (<xref rid="b28-ol-0-0-7870" ref-type="bibr">28</xref>) strongly indicated that opioids, including morphine and fentanyl, can promote tumor metastasis and recurrence. Clinical trials (<xref rid="b29-ol-0-0-7870" ref-type="bibr">29</xref>,<xref rid="b30-ol-0-0-7870" ref-type="bibr">30</xref>) have demonstrated that morphine can accelerate the growth of breast tumors. Consequently, paravertebral anesthesia and analgesia combined with GA led to a lower incidence of cancer recurrence or metastasis. Recent research indicates that the association of opioids with tumor behavior is complex and remains unclear (<xref rid="b31-ol-0-0-7870" ref-type="bibr">31</xref>).</p>
<p>The present study compared the anti-metastatic effect of GA and GEA on tumor-bearing rats with hepatectomy. The results revealed that the anti-metastatic effect of GEA is significant superior to GA. Furthermore, the mechanism of the two anesthesia methods on tumor metastasis and angiogenesis was investigated. As the results of the present study demonstrate, one possible mechanism by which GEA suppresses tumor metastasis and angiogenesis is the improvement of the expression of interferon-&#x03B3; (IFN-&#x03B3;) and the inhibition of transforming growth factor-&#x03B1; (TGF-&#x03B1;), VEGF and p-STAT3.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Materials</title>
<p>The rat hepatic cancer cell line Morris hepatoma 3924A was purchased from American Type Culture Collection (Manassas, VA, USA) Morphine, bupivacaine and fentanyl were purchased from Shanghai Sangon Biotechnology Co., Ltd. (Shanghai, China). The cell line was cultured at 37&#x00B0;C in a humidified atmosphere containing 5&#x0025; CO<sub>2</sub> in Dulbecco&#x0027;s modified Eagle&#x0027;s medium with 10&#x0025; fetal bovine serum (FBS), 100 U ml<sup>&#x2212;1</sup> penicillin and 100 mg ml<sup>&#x2212;1</sup> streptomycin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 30 male American Certification Institute (ACI) rats (age, 12&#x2013;18 weeks; weight, 200&#x2013;250 g) were purchased from the Experimental Animal Center of Changchun Biological Institute (Changchun, China), and they were housed at a temperature of 20&#x2013;22&#x00B0;C, relative humidity of 50&#x2013;60&#x0025; and 12/12 h light/dark cycles. They were also provided with free access to food and water. The 7-0 injury-free operative sutures were purchased from Shanghai Surgical Suture Company. ELISA kit and antibodies used in the present study were purchased from Invitrogen (Thermo Fisher Scientific, Inc.). Details were as follows: IFN-&#x03B3; ELISA kit (cat no. BMS621); TGF-&#x03B1; ELISA kit (cat no. EHTGFA); VEGF ELISA kit (cat no. ERVEGFACL); phospho-STAT3 (Tyr705) polyclonal antibody (cat no. 44-380G; dilution, 1:1,000); and phospho-EGFR (Tyr1086) polyclonal antibody (cat no. 36-9700; dilution, 1:500). The anti-rabbit IgG secondary antibody, horseradish peroxidase (cat no. P7899; dilution, 1:100,000) was provided by Sigma-Aldrich (Merck KGaA; Darmstadt, Germany).</p>
</sec>
<sec>
<title>Animals and the tumor xenograft model</title>
<p>All animal experiments were performed in compliance with the Animal Management Rules of the Ministry of Health of the People&#x0027;s Republic of China (<uri xlink:href="http://www.medste.gd.cn/Html/sciedu/sysgl/Class3141/24961720080910094400.html">http://www.medste.gd.cn/Html/sciedu/sysgl/Class3141/24961720080910094400.html</uri>) and approved by the Animal Care and Use Committee of Jilin University (Changchun, China). All animals were pathogen-free and allowed ad libitum access to food and water. To produce the tumor xenograft model, MH3924A cells in the logarithmic phase were injected subcutaneously into the upper axillary fossa of the male ACI rats (12&#x2013;18 weeks, n=10 per group). After 14 days, subcutaneous tumors were surgically removed. Fresh tumor tissues were chosen and divided into l-mm<sup>3</sup> tumor pieces. The male rats were fixed on a frame prior to anesthesia, then the abdominal body hair was removed and the animals were disinfected with iodine. A 5-ml syringe was placed at the back of the fixed rats to raise the abdomen of the rats for surgical convenience. Next, when the size of incision in upper abdomen reached ~0.5 cm, the skin, subcutaneous tissue and peritoneal tissue was consecutively cut and then the rat liver was exposed. The left lobe was cleaned with wet cotton and the liver capsule was punctured with ophthalmic scissors, making a further long cut under the capsule. Next, the as-prepared tumor tissue was inserted into the long cut, which was closed with 7-0 microscopic sutures. Prior to abdominal closure, it should be confirmed that there was no blister tissue out and no bleeding.</p>
</sec>
<sec>
<title>GEA</title>
<p>When the tumor volume reached ~300 mm<sup>3</sup>, these tumor-bearing rats were randomly divided into three treatment groups: One group was treated with hepatectomy and general anesthesia combined with epidural block (group G &#x002B; E), one group was treated with hepatectomy and general anesthesia (group G) and one group, the control group, did not undergo any treatment (group C). There were 10 rats included in each group.</p>
</sec>
<sec>
<title>GA</title>
<p>A simple tumor resection was performed under general anesthesia. Specifically, sevoflurane together with oxygen was injected into a self-made anesthesia box. Next, the retraction response of rat toes to stimulus was continuously assessed to determine the degree of anesthesia. When the retraction response of rat toes to stimulus disappeared, tracheal incubation was conducted for the rat by transmission light intubation. Specifically, the 50-W illuminant was placed 5 cm away from the neck of the rat. In this way, the light could pass through the neck skin and trachea wall in sequence. A mini sized spatula with a 145&#x00B0; angle were used to push away the tongue for clear observation of the epiglottis and vocal cord movement under the transmitted light, thus an 18 G cannula was inserted under a bright view. The regular movement of the rat thorax was observed following connection with the ventilator with mechanical ventilation. The parameters of the ventilator were set as follows: Breathing rate, 55/min; tidal volume, 3 ml/100 g; inspiration rate: expiration rate, 1.5:1; sevoflurane concentration, 2&#x2013;3&#x0025; (v/v). To maintain the anesthesia effect, morphine (0.2 ml/100 g, 10&#x0025; solution) was injected intraperitoneally. When the rats woke following surgery, the endotracheal tube was removed.</p>
</sec>
<sec>
<title>Epidural anesthesia</title>
<p>Perioperative epidural analgesia consisted of a bolus of 6&#x2013;9 ml of 0.25&#x0025; bupivacaine followed by a postoperative infusion of bupivacaine (0.1&#x2013;0.2&#x0025;) with or without 2 &#x00B5;g/ml of fentanyl at a rate of 6&#x2013;9 ml/h. Specifically, the limbs and head of the rat were fixed following the success of tracheal incubation under general anesthesia. A self-made sterile PVC epidural catheter with diameter of 0.3 mm was inserted via removing the eighth or ninth thoracic spinous process using a vertical needling and was advanced 1 cm cephalad into the epidural space. Subsequently, 0.25&#x0025; of bupivacaine was micro-injected via the epidural catheter.</p>
</sec>
<sec>
<title>Hepatectomy</title>
<p>According to observations, the tumor size was suitable for hepatectomy and no distant metastasis was observed at day 14 following inoculation with tumor cells. Hepatectomy was conducted following successful anesthesia with the assistance of undergraduate students majoring in liver surgery (Departments of General Surgery, China-Japan Union Hospital Jilin University, Changchun, China). Specifically, the skin, subcutaneous tissue and peritoneal tissue was consecutively removed from the original upper abdomen incision. Next, the left lobe of the liver was exposed and the megascopic <italic>in situ</italic> tumor tissue was removed, as was 5 mm normal liver tissue around the edge of tumor. The 7-0 microscopic suture was used to close the abdomen following the confirmation of no bleeding.</p>
</sec>
<sec>
<title>Blood sample collection and ELISA assay</title>
<p>Venous blood samples were collected from orbits of rats immediately prior to surgery and at 2, 7 and 30 days following surgery. The blood samples were left to clot at room temperature and then stored overnight in a refrigerator to contract the clot. The clot was removed and the remaining material was centrifuged at 4,000 &#x00D7; g for 5 min and the resulting serum was stored at &#x2212;80&#x00B0;C until analysis. Plasma levels of IFN-&#x03B3;, TGF-&#x03B1; and VEGF were measured by an ELISA. Plasma levels of each cytokine were measured in duplicate from one aliquot of each sample and the mean value from these two measurements was used as the final concentration. Quantification was achieved using an automated microplate reader. Concentrations of all cytokines were reported in pg/ml. The rats were sacrificed 30 days following surgery. The lungs were removed and collected for the following experiments. The metastatic nodes in the lungs of mice were visualized by fixing them in Bouin&#x0027;s solution (saturated picric acid: Formalin: Acetic acid, 15:5:1) at room temperature for 24 h and photographed using a high-definition digital camera (IXUS 110, Canon Inc., Tokyo, Japan) to evaluate the anti-metastatic effects of general anesthetic and general anesthetic with epidural block.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>For each group, 0.1 g of the lung tissue was collected for protein extraction and lysed using a Dounce homogenizer (20 strokes) in 400 &#x00B5;l of buffer containing 50 mM tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl), pH 7.6, 42 mM KCl, 5 mM MgCl<sub>2</sub>, 1 mM dithiothreitol (DTT), 0.5&#x0025; 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate, 1 mM phenylmethylsulfonyl-fluoride and 1 &#x00B5;g/ml leupeptin (Sigma-Aldrich; Merck KGaA), and then centrifuged at 15,000 &#x00D7; g for 20 min at 4&#x00B0;C. The protein concentrations of the lysates were determined by BCA protein assay. Equal amounts (50 &#x00B5;g) of protein were separated on a 10&#x0025; SDS-PAGE and transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5&#x0025; non-fat milk in Tris-buffered saline/0.1&#x0025; Tween-20 for 2 h, subsequently blotted with respective primary antibodies overnight at 4&#x00B0;C as described previously in the materials section, and then blotted with horseradish peroxidase-conjugated secondary antibody at 37&#x00B0;C for 1 h. The protein bands were visualized using an enhanced chemiluminescent agent (Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China). Protein levels were quantified by density analysis using ImageJ software version 1.62 (National Institutes of Health, Bethesda, MD, USA), and expressed as the interest protein/internal control.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Data from &#x2265;3 groups were compared using one-way analysis of variance followed by Dunnett&#x0027;s post-hoc test using the SPSS software package (version 13.0; SPSS Inc., Chicago, IL, USA). The experiments were performed in triplicate and the data are presented as the mean &#x00B1; standard deviation. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>The anti-metastatic effects of GA and GEA</title>
<p>The evaluation on the <italic>in vivo</italic> anti-metastatic activity of general anesthesia and epidural anesthesia was performed. In the <italic>in vivo</italic> experiment, the rats were sacrificed 30 days after surgery and the lungs were dissected. The average numbers of metastatic nodules on the lung surface in different groups were counted. Representative photos of the lungs with the metastatic nudes are presented in <xref rid="f1-ol-0-0-7870" ref-type="fig">Fig. 1</xref>. As depicted in <xref rid="tI-ol-0-0-7870" ref-type="table">Table I</xref>, the number of metastasis nodules in the G &#x002B; E group was 18&#x00B1;6, which was significantly (P&#x003C;0.05) less than that in group C (40&#x00B1;6) or group G (38&#x00B1;5). This result indicated that GEA could effectively inhibit lung metastasis compared with GA following hepatectomy. The conditions of abdominal lymph node metastasis, the rate of malignant ascites and number of abdominal wall planting nodules also validated this conclusion. As presented in <xref rid="tI-ol-0-0-7870" ref-type="table">Table I</xref>, the number of animals for which there was a presence of abdominal lymph node metastasis was significantly lower for group G &#x002B; E (1/10) than for group C (7/10) or group G (6/10). For group C and group G, the rates of malignant ascites were higher than that of group G &#x002B; E, which demonstrated the low metastatic rate following surgery with epidural anesthesia. Abdominal wall-implanted nodules represented another important evaluation index for metastatic condition. According to <xref rid="tI-ol-0-0-7870" ref-type="table">Table I</xref>, the number of rats with abdominal wall-implanted nodules in group G &#x002B; E was 2/10, which was significantly lower than that for group C (8/10) or group G (5/10). Hepatectomy with different anesthetic techniques revealed different rates of tumor metastasis. Notably, GEA could effectively inhibit tumor metastasis compared to GA following hepatectomy.</p>
</sec>
<sec>
<title>Changes in cytokine concentration in the serum of rats that underwent different treatments determined by ELISA</title>
<p>As shown in <xref rid="f2-ol-0-0-7870" ref-type="fig">Fig. 2A</xref>, there was no significant difference in IFN-&#x03B3; levels between groups C, G and G &#x002B; E on day 0. On day 2, the concentration of IFN-&#x03B3; in group G &#x002B; E (3,411&#x00B1;232 pg/ml) was significantly higher than that in group C (1,497&#x00B1;146 pg/ml) and G (2,578&#x00B1;165 pg/ml). On day 7 and day 30, there was no significant difference between group C and G, but these concentrations were significantly higher than those in group G &#x002B; E. For group G &#x002B; E, the concentration of IFN-&#x03B3; at day 7 and day 30 was slightly lower than that on day 2. Similarly, there was no significant difference in regard to concentrations of TGF-&#x03B1; and VEGF between group C, G and G &#x002B; E on day 0 (<xref rid="f2-ol-0-0-7870" ref-type="fig">Fig. 2B and C</xref>). On the following days, concentrations of TGF-&#x03B1; and VEGF were significantly lower in group G &#x002B; E than in groups C and G (P&#x003C;0.05). Notably, the concentration of TGF-&#x03B1; increased slowly over time following surgery. However, the concentration of VEGF was at its minimum on day 7. Groups C and G exhibited increases in the concentration of TGF-&#x03B1; and VEGF, whereas the concentration in group G &#x002B; E rats remained lower than those in groups C and G.</p>
</sec>
<sec>
<title>Levels of phosphorylated STAT3 (p-STAT3) and p-VEGF in lung metastasis tissues determined by western blot analysis</title>
<p>To investigate the mechanism of the anesthesia-induced anti-metastatic effect further, levels of p-STAT3 and p-EGFR lung metastatic tissues were determined by western blot analysis (<xref rid="f3-ol-0-0-7870" ref-type="fig">Fig. 3</xref>). The levels of p-STAT3 and p-EGFR in group G were slightly lower than those in group C. It was shown that there were significantly (P&#x003C;0.05) lower levels of p-STAT3 and p-EGFR in group G &#x002B; E than in groups C and G. Evidence indicates that aberrant STAT3 signaling promotes the initiation and progression of human cancer by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion and metastasis (<xref rid="b32-ol-0-0-7870" ref-type="bibr">32</xref>&#x2013;<xref rid="b34-ol-0-0-7870" ref-type="bibr">34</xref>). Additionally, expression of EGFR is altered in a variety of human cancer types, including carcinoma of the lung, breast, head and neck, ovary and bladder, as well as in glioma (<xref rid="b35-ol-0-0-7870" ref-type="bibr">35</xref>&#x2013;<xref rid="b37-ol-0-0-7870" ref-type="bibr">37</xref>). STAT3 and EGFR serve notable roles in tumor development and metastasis (<xref rid="b34-ol-0-0-7870" ref-type="bibr">34</xref>,<xref rid="b38-ol-0-0-7870" ref-type="bibr">38</xref>). The results of the present study indicated that GEA significantly inhibited tumor metastasis by reducing levels of p-STAT3 and p-EGFR.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The perioperative period is a critical period of damage to the body&#x0027;s defense mechanism and has a substantial influence on the long-term prognosis of tumor patients. The role of anesthesia in improving the long-term prognosis of patients following surgery has been known and taken seriously in recent years.</p>
<p>It has been reported that there are four major mechanisms that surgery could contribute to an increase in tumor metastasis: i) The operation and touch of the tumor during surgery increased the chance of tumor cells releasing into the bloodstream (<xref rid="b39-ol-0-0-7870" ref-type="bibr">39</xref>); ii) Tumors <italic>in situ</italic> (TIS) serve a role in inhibiting angiogenesis: In surgery, the resection of TIS disrupts this line of defense, with the residual lesions promoting diseases and inducing the growth of blood vessels to increase the risk of tumor metastasis (<xref rid="b40-ol-0-0-7870" ref-type="bibr">40</xref>); iii) Perioperative immune suppression: Levels of epinephrine and norepinephrine during the perioperative period are substantially increased, which is considered to be the key to the connection between stress response and cancer progression (<xref rid="b41-ol-0-0-7870" ref-type="bibr">41</xref>); iv) The increase in local and systemic growth factor (EGF and VEGF) release in surgery promotes the recurrence of local and distant tumors (<xref rid="b42-ol-0-0-7870" ref-type="bibr">42</xref>). Furthermore, anti-angiogenic factors, including angiostatin and endostatin, decrease during surgery (<xref rid="b43-ol-0-0-7870" ref-type="bibr">43</xref>). Catecholamine promotes growth in a variety of tumor types by activating the STAT3 signaling pathway to increase the level of VEGF and inhibit the cellular immune response (<xref rid="b5-ol-0-0-7870" ref-type="bibr">5</xref>).</p>
<p>In the present study, the levels of IFN-&#x03B3; in the plasma of rats in group G &#x002B; E were higher than those in the two other groups, whereas the levels of VEGF and TGF-&#x03B1; in group G &#x002B; E were lower than those in other two groups, as was the degree of STAT3 activation. The present study indicates that compared with GA, GEA can reduce the incidence of liver cancer metastasis following surgery. A possible mechanism may include the inhibition of STAT3 and relevant cytokines, including IFN-&#x03B3; and TGF-&#x03B1;.</p>
<p>IFN-&#x03B3;, which is secreted by T cells, can suppress tumor cell proliferation, upregulate the expression of surface major histocompatibility complex antigens and tumor necrosis factor and prevent tumor growth via inhibition of tumor angiogenesis and other mechanisms (<xref rid="b44-ol-0-0-7870" ref-type="bibr">44</xref>). A previous study demonstrated that IFN-&#x03B3; can decrease the defense of tumors cells escaping immune system by regulating expression of the Fas cell surface death receptor/Fas ligand and enhancing sensitivity to Fas-mediated apoptosis, thus inhibiting the malignant proliferation of tumor cells (<xref rid="b45-ol-0-0-7870" ref-type="bibr">45</xref>).</p>
<p>EGFR is a membrane-bound receptor tyrosine kinase that belongs to the ErbB subfamily (<xref rid="b46-ol-0-0-7870" ref-type="bibr">46</xref>). On ligand binding, EGFR initiates the activation of a series of cellular signal transduction pathways that regulate cell proliferation and survival (<xref rid="b47-ol-0-0-7870" ref-type="bibr">47</xref>). The primary ligands for EGFR include EGF and TGF-&#x03B1; in liver cells (<xref rid="b48-ol-0-0-7870" ref-type="bibr">48</xref>). TGF-&#x03B1; produced by liver cells can bind with EGFR to promote the proliferation of liver cells by autocrine, or increase the proliferation of the vascular endothelium by paracrine (<xref rid="b6-ol-0-0-7870" ref-type="bibr">6</xref>). EGFR is activated by ligand binding, which causes it to homodimerize, activating downstream pathways, including the RAS proto-oncogene, GTPase/Raf proto-oncogene, serine/threonine kinase mitogen-activated protein kinase pathway, the Janus kinase (JAK)/STAT pathway and the phosphoinositide 3-kinase/RAC serine/threonine-protein kinase pathway (<xref rid="b49-ol-0-0-7870" ref-type="bibr">49</xref>). Two possible pathways for STAT3 activation exist, a JAK-dependent mechanism and a JAK-independent one, which initiates dimer formation of STAT3 in the cytoplasm. Thereafter, activated STAT3 transfers into the nucleus, binds to specific DNA sequences and induces transcription of target genes (<xref rid="b47-ol-0-0-7870" ref-type="bibr">47</xref>,<xref rid="b50-ol-0-0-7870" ref-type="bibr">50</xref>). This sequential process promotes tumor cell proliferation and inhibits apoptosis by regulating expression of the apoptosis suppressor genes, such as MCL1, BCL2 family apoptosis regulator and BCL2-like 1, and cell cycle regulatory factors, such as cyclin D1/D2 and MYC proto-oncogene, BHLH transcription factor (<xref rid="b3-ol-0-0-7870" ref-type="bibr">3</xref>).</p>
<p>In the present study, the expression levels of VEGF and TGF-&#x03B1; in group C were significantly higher than those in group G; however, those in group G were higher than those in group G &#x002B; E. Overexpression of EGFR and its relevant ligands or the sequential activation of downstream signal pathways is observed in numerous tumor types (<xref rid="b37-ol-0-0-7870" ref-type="bibr">37</xref>,<xref rid="b38-ol-0-0-7870" ref-type="bibr">38</xref>). The formation of tumors is promoted by the following methods: Overexpression of EGFR triggers the enhancement of downstream signal transduction (<xref rid="b51-ol-0-0-7870" ref-type="bibr">51</xref>); the mutation of EGFR or overexpression of its ligands results in continuous EGFR activation (<xref rid="b52-ol-0-0-7870" ref-type="bibr">52</xref>); the function of autocrine loop is enhanced (<xref rid="b53-ol-0-0-7870" ref-type="bibr">53</xref>), mechanisms of downregulation of oncogenic receptors are lost (<xref rid="b54-ol-0-0-7870" ref-type="bibr">54</xref>); and abnormal signal transduction pathways are activated (<xref rid="b55-ol-0-0-7870" ref-type="bibr">55</xref>). In the present study, the increase in the expression of EGFR and its ligand demonstrated that the EGFR signal transduction pathway alters the formation of liver cancer metastasis via at least two mechanisms: The overexpression of TGF-&#x03B1; and EGFR, leading to the formation of an autocrine loop and increased downstream signal transduction, respectively. STAT3 is an oncogene that is closely associated with tumor development, evolvement, differentiation and immunity (<xref rid="b18-ol-0-0-7870" ref-type="bibr">18</xref>,<xref rid="b19-ol-0-0-7870" ref-type="bibr">19</xref>). The sustained activation or overexpression of STAT3 is frequently observed in skin, lung and breast cancer (<xref rid="b56-ol-0-0-7870" ref-type="bibr">56</xref>). To the best of our knowledge, mutations to STAT3 have not yet been observed, so we hypothesize that the sustained activation of STAT3 is triggered by enhancement of the intensity of upstream signal transduction pathways.</p>
<p>Song and Grandis (<xref rid="b57-ol-0-0-7870" ref-type="bibr">57</xref>) demonstrated that cell lines overexpressing TGF-&#x03B1; exhibited sustained activation of STAT3, and the addition of exogenous TGF-&#x03B1; could enhance the activation of squamous cell carcinoma of the head and neck. For certain tumors, the sustained activation of STAT3 resulted in the enhancement of activation of EGFR signal transduction pathways (<xref rid="b57-ol-0-0-7870" ref-type="bibr">57</xref>). STAT3 binds to activated EGFR via SH2 domains; stimulation of EGFR induces Tyr705 phosphorylation of STAT3, which is a prerequisite for dimerization of STATs, which again occurs via the SH2 domains (<xref rid="b58-ol-0-0-7870" ref-type="bibr">58</xref>). The dimerization of tyrosine-phosphorylated STATs leads to their nuclear accumulation, DNA binding at specific sites and the transcriptional activation of target genes (<xref rid="b57-ol-0-0-7870" ref-type="bibr">57</xref>). Research on breast cancer, squamous cell carcinoma of the head and neck and epidermoid cancer has revealed that sustained activation of STAT3 is relevant to the formation of the EGFR/TGF-&#x03B1; autocrine loop (<xref rid="b59-ol-0-0-7870" ref-type="bibr">59</xref>&#x2013;<xref rid="b61-ol-0-0-7870" ref-type="bibr">61</xref>).</p>
<p>The present study revealed that the metastasis of liver cancer was decreased in rats that underwent surgery with GEA compared with those that underwent GA. The results demonstrated that the mechanism by which this occurred may be associated with the inhibition of STAT3 and certain relevant cytokines. However, these results were obtained from animal experiments, which require careful consideration and further confirmation in clinical trials.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-ol-0-0-7870"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>RX</given-names></name><name><surname>Seto</surname><given-names>WK</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Yuen</surname><given-names>MF</given-names></name></person-group><article-title>Epidemiology of hepatocellular carcinoma in the Asia-pacific region</article-title><source>Gut Liver</source><volume>10</volume><fpage>332</fpage><lpage>339</lpage><year>2016</year><pub-id pub-id-type="doi">10.5009/gnl15257</pub-id><pub-id pub-id-type="pmid">27114433</pub-id></element-citation></ref>
<ref id="b2-ol-0-0-7870"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Updated treatment approach to hepatocellular carcinoma</article-title><source>J Gastroenterol</source><volume>40</volume><fpage>225</fpage><lpage>235</lpage><year>2005</year><pub-id pub-id-type="doi">10.1007/s00535-005-1566-3</pub-id><pub-id pub-id-type="pmid">15830281</pub-id></element-citation></ref>
<ref id="b3-ol-0-0-7870"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buggy</surname><given-names>DJ</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name></person-group><article-title>Epidural anesthesia and analgesia: Better outcome after major surgery? Growing evidence suggests so</article-title><source>BMJ</source><volume>319</volume><fpage>530</fpage><lpage>531</lpage><year>1999</year><pub-id pub-id-type="doi">10.1136/bmj.319.7209.530</pub-id><pub-id pub-id-type="pmid">10463878</pub-id></element-citation></ref>
<ref id="b4-ol-0-0-7870"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Hirai</surname><given-names>M</given-names></name><name><surname>Katsube</surname><given-names>T</given-names></name><name><surname>Murayama</surname><given-names>M</given-names></name><name><surname>Hamaguchi</surname><given-names>K</given-names></name><name><surname>Shimakawa</surname><given-names>T</given-names></name><name><surname>Naritake</surname><given-names>Y</given-names></name><name><surname>Hosokawa</surname><given-names>T</given-names></name><name><surname>Kajiwara</surname><given-names>T</given-names></name></person-group><article-title>Suppression of cellular immunity by surgical stress</article-title><source>Surgery</source><volume>127</volume><fpage>329</fpage><lpage>336</lpage><year>2000</year><pub-id pub-id-type="doi">10.1067/msy.2000.103498</pub-id><pub-id pub-id-type="pmid">10715990</pub-id></element-citation></ref>
<ref id="b5-ol-0-0-7870"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Eliyahu</surname><given-names>S</given-names></name></person-group><article-title>The price of anticancer intervention</article-title><source>Does surgery promote metastasis? Lancet Oncol</source><volume>3</volume><fpage>578</fpage><lpage>579</lpage><year>2002</year><pub-id pub-id-type="pmid">12233735</pub-id></element-citation></ref>
<ref id="b6-ol-0-0-7870"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Eliyahu</surname><given-names>S</given-names></name><name><surname>Page</surname><given-names>GG</given-names></name><name><surname>Yirmiya</surname><given-names>R</given-names></name><name><surname>Shakhar</surname><given-names>G</given-names></name></person-group><article-title>Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity</article-title><source>Int J Cancer</source><volume>80</volume><fpage>880</fpage><lpage>888</lpage><year>1999</year><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19990315)80:6&#x003C;880::AID-IJC14&#x003E;3.0.CO;2-Y</pub-id><pub-id pub-id-type="pmid">10074922</pub-id></element-citation></ref>
<ref id="b7-ol-0-0-7870"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deiner</surname><given-names>S</given-names></name><name><surname>Silverstein</surname><given-names>JH</given-names></name></person-group><article-title>Long-term outcomes in elderly surgical patients</article-title><source>Mt Sinai J Med</source><volume>79</volume><fpage>95</fpage><lpage>106</lpage><year>2012</year><pub-id pub-id-type="doi">10.1002/msj.21288</pub-id><pub-id pub-id-type="pmid">22238042</pub-id></element-citation></ref>
<ref id="b8-ol-0-0-7870"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deflandre</surname><given-names>E</given-names></name><name><surname>Lacroix</surname><given-names>S</given-names></name></person-group><article-title>It is time for anesthetists to act as perioperative physicians</article-title><source>Minerva Anestesiol</source><volume>82</volume><fpage>257</fpage><lpage>258</lpage><year>2016</year><pub-id pub-id-type="pmid">26381357</pub-id></element-citation></ref>
<ref id="b9-ol-0-0-7870"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>TA</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Sanders</surname><given-names>AJ</given-names></name><name><surname>Lane</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>WG</given-names></name></person-group><chapter-title>Cancer invasion and metastasis: Molecular and cellular perspective</chapter-title><source>Metastatic Cancer Clinical Biological Perspectives 2013</source><person-group person-group-type="editor"><name><surname>Jandial</surname><given-names>R</given-names></name></person-group><publisher-name>Landes Bioscience</publisher-name><publisher-loc>Austin, TX</publisher-loc><fpage>135</fpage><lpage>168</lpage><year>2013</year></element-citation></ref>
<ref id="b10-ol-0-0-7870"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Yoshioka</surname><given-names>I</given-names></name><name><surname>Ohashi</surname><given-names>Y</given-names></name><name><surname>Matsuo</surname><given-names>M</given-names></name><name><surname>Harimaya</surname><given-names>Y</given-names></name><name><surname>Tsukada</surname><given-names>K</given-names></name><name><surname>Saiki</surname><given-names>I</given-names></name></person-group><article-title>Increased surgical stress promotes tumor metastasis</article-title><source>Surgery</source><volume>133</volume><fpage>547</fpage><lpage>555</lpage><year>2003</year><pub-id pub-id-type="doi">10.1067/msy.2003.141</pub-id><pub-id pub-id-type="pmid">12773983</pub-id></element-citation></ref>
<ref id="b11-ol-0-0-7870"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ucuzian</surname><given-names>AA</given-names></name><name><surname>Gassman</surname><given-names>AA</given-names></name><name><surname>East</surname><given-names>AT</given-names></name><name><surname>Greisler</surname><given-names>HP</given-names></name></person-group><article-title>Molecular mediators of angiogenesis</article-title><source>J Burn Care Res</source><volume>31</volume><fpage>158</fpage><lpage>175</lpage><year>2010</year><pub-id pub-id-type="doi">10.1097/BCR.0b013e3181c7ed82</pub-id><pub-id pub-id-type="pmid">20061852</pub-id></element-citation></ref>
<ref id="b12-ol-0-0-7870"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Distler</surname><given-names>JH</given-names></name><name><surname>Hirth</surname><given-names>A</given-names></name><name><surname>Kurowska-Stolarska</surname><given-names>M</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Distler</surname><given-names>O</given-names></name></person-group><article-title>Angiogenic and angiostatic factors in the molecular control of angiogenesis</article-title><source>Q J Nucl Med</source><volume>47</volume><fpage>149</fpage><lpage>161</lpage><year>2003</year><pub-id pub-id-type="pmid">12897707</pub-id></element-citation></ref>
<ref id="b13-ol-0-0-7870"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>M</given-names></name></person-group><article-title>Integrative signaling in angiogenesis</article-title><source>Mol Cell Biochem</source><volume>264</volume><fpage>99</fpage><lpage>102</lpage><year>2004</year><pub-id pub-id-type="doi">10.1023/B:MCBI.0000044379.25823.03</pub-id><pub-id pub-id-type="pmid">15544039</pub-id></element-citation></ref>
<ref id="b14-ol-0-0-7870"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>ZC</given-names></name></person-group><article-title>STAT3: A critical transcription activator in angiogenesis</article-title><source>Med Res Rev</source><volume>28</volume><fpage>185</fpage><lpage>200</lpage><year>2008</year><pub-id pub-id-type="doi">10.1002/med.20101</pub-id><pub-id pub-id-type="pmid">17457812</pub-id></element-citation></ref>
<ref id="b15-ol-0-0-7870"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeben</surname><given-names>A</given-names></name><name><surname>Landuyt</surname><given-names>B</given-names></name><name><surname>Highley</surname><given-names>MS</given-names></name><name><surname>Wildiers</surname><given-names>H</given-names></name><name><surname>Van Oosterom</surname><given-names>AT</given-names></name><name><surname>De Bruijn</surname><given-names>EA</given-names></name></person-group><article-title>Vascular endothelial growth factor and angiogenesis</article-title><source>Pharmacol Rev</source><volume>56</volume><fpage>549</fpage><lpage>580</lpage><year>2004</year><pub-id pub-id-type="doi">10.1124/pr.56.4.3</pub-id><pub-id pub-id-type="pmid">15602010</pub-id></element-citation></ref>
<ref id="b16-ol-0-0-7870"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senger</surname><given-names>DR</given-names></name><name><surname>Galli</surname><given-names>SJ</given-names></name><name><surname>Dvorak</surname><given-names>AM</given-names></name><name><surname>Perruzzi</surname><given-names>CA</given-names></name><name><surname>Harvey</surname><given-names>VS</given-names></name><name><surname>Dvorak</surname><given-names>HF</given-names></name></person-group><article-title>Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid</article-title><source>Science</source><volume>219</volume><fpage>983</fpage><lpage>985</lpage><year>1983</year><pub-id pub-id-type="doi">10.1126/science.6823562</pub-id><pub-id pub-id-type="pmid">6823562</pub-id></element-citation></ref>
<ref id="b17-ol-0-0-7870"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>DW</given-names></name><name><surname>Cachianes</surname><given-names>G</given-names></name><name><surname>Kuang</surname><given-names>WJ</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name></person-group><article-title>Vascular endothelial growth factor is a secreted angiogenic mitogen</article-title><source>Science</source><volume>246</volume><fpage>1306</fpage><lpage>1309</lpage><year>1989</year><pub-id pub-id-type="doi">10.1126/science.2479986</pub-id><pub-id pub-id-type="pmid">2479986</pub-id></element-citation></ref>
<ref id="b18-ol-0-0-7870"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>TX</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>AC</given-names></name><name><surname>Ali-Osman</surname><given-names>F</given-names></name><name><surname>Sawaya</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name></person-group><article-title>Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis</article-title><source>Oncogene</source><volume>23</volume><fpage>3550</fpage><lpage>3560</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/sj.onc.1207383</pub-id><pub-id pub-id-type="pmid">15116091</pub-id></element-citation></ref>
<ref id="b19-ol-0-0-7870"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>TX</given-names></name><name><surname>Huang</surname><given-names>FJ</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Sawaya</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name></person-group><article-title>Activation of stat3 in human melanoma promotes brain metastasis</article-title><source>Cancer Res</source><volume>66</volume><fpage>3188</fpage><lpage>3196</lpage><year>2006</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2674</pub-id><pub-id pub-id-type="pmid">16540670</pub-id></element-citation></ref>
<ref id="b20-ol-0-0-7870"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Exadaktylos</surname><given-names>AK</given-names></name><name><surname>Buggy</surname><given-names>DJ</given-names></name><name><surname>Moriarty</surname><given-names>DC</given-names></name><name><surname>Mascha</surname><given-names>E</given-names></name><name><surname>Sessler</surname><given-names>DI</given-names></name></person-group><article-title>Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?</article-title><source>Anesthesiology</source><volume>105</volume><fpage>660</fpage><lpage>664</lpage><year>2006</year><pub-id pub-id-type="doi">10.1097/00000542-200610000-00008</pub-id><pub-id pub-id-type="pmid">17006061</pub-id></element-citation></ref>
<ref id="b21-ol-0-0-7870"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Rensing</surname><given-names>H</given-names></name><name><surname>Ziegenfuss</surname><given-names>T</given-names></name></person-group><article-title>Anesthesia and perioperative immune function</article-title><source>Anaesthesist</source><volume>47</volume><fpage>538</fpage><lpage>556</lpage><year>1998</year><comment>(In German)</comment><pub-id pub-id-type="doi">10.1007/s001010050595</pub-id><pub-id pub-id-type="pmid">9740928</pub-id></element-citation></ref>
<ref id="b22-ol-0-0-7870"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borsook</surname><given-names>D</given-names></name><name><surname>George</surname><given-names>E</given-names></name><name><surname>Kussman</surname><given-names>B</given-names></name><name><surname>Becerra</surname><given-names>L</given-names></name></person-group><article-title>Anesthesia and perioperative stress: Consequences on neural networks and postoperative behaviors</article-title><source>Prog Neurobiol</source><volume>92</volume><fpage>601</fpage><lpage>612</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.pneurobio.2010.08.006</pub-id><pub-id pub-id-type="pmid">20727935</pub-id></element-citation></ref>
<ref id="b23-ol-0-0-7870"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>AH</given-names></name><name><surname>Buggy</surname><given-names>DJ</given-names></name></person-group><article-title>Can anaesthetic and analgesic techniques for cancer surgery affect cancer recurrence and metastasis?</article-title><source>Curr Anesthesiology Rep</source><volume>5</volume><fpage>190</fpage><lpage>202</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s40140-015-0108-7</pub-id></element-citation></ref>
<ref id="b24-ol-0-0-7870"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahabi</surname><given-names>S</given-names></name><name><surname>Eatemadi</surname><given-names>A</given-names></name></person-group><article-title>Effects of anesthetic and analgesic techniques on cancer metastasis</article-title><source>Biomed Pharmacother</source><volume>87</volume><fpage>1</fpage><lpage>7</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.biopha.2016.11.137</pub-id><pub-id pub-id-type="pmid">28040593</pub-id></element-citation></ref>
<ref id="b25-ol-0-0-7870"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogren</surname><given-names>SO</given-names></name><name><surname>Holm</surname><given-names>AC</given-names></name></person-group><article-title>Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia</article-title><source>J Neural Transm</source><volume>47</volume><fpage>253</fpage><lpage>271</lpage><year>1980</year><pub-id pub-id-type="doi">10.1007/BF01247321</pub-id><pub-id pub-id-type="pmid">6446594</pub-id></element-citation></ref>
<ref id="b26-ol-0-0-7870"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacerdote</surname><given-names>P</given-names></name><name><surname>Bianchi</surname><given-names>M</given-names></name><name><surname>Gaspani</surname><given-names>L</given-names></name><name><surname>Manfredi</surname><given-names>B</given-names></name><name><surname>Maucione</surname><given-names>A</given-names></name><name><surname>Terno</surname><given-names>G</given-names></name><name><surname>Ammatuna</surname><given-names>M</given-names></name><name><surname>Panerai</surname><given-names>AE</given-names></name></person-group><article-title>The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients</article-title><source>Anesth Analg</source><volume>90</volume><fpage>1411</fpage><lpage>1414</lpage><year>2000</year><pub-id pub-id-type="doi">10.1097/00000539-200006000-00028</pub-id><pub-id pub-id-type="pmid">10825330</pub-id></element-citation></ref>
<ref id="b27-ol-0-0-7870"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeager</surname><given-names>MP</given-names></name><name><surname>Colacchio</surname><given-names>TA</given-names></name><name><surname>Yu</surname><given-names>CT</given-names></name><name><surname>Hildebrandt</surname><given-names>L</given-names></name><name><surname>Howell</surname><given-names>AL</given-names></name><name><surname>Weiss</surname><given-names>J</given-names></name><name><surname>Guyre</surname><given-names>PM</given-names></name></person-group><article-title>Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers</article-title><source>Anesthesiology</source><volume>83</volume><fpage>500</fpage><lpage>508</lpage><year>1995</year><pub-id pub-id-type="doi">10.1097/00000542-199509000-00008</pub-id><pub-id pub-id-type="pmid">7661350</pub-id></element-citation></ref>
<ref id="b28-ol-0-0-7870"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasamura</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Iida</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Murata</surname><given-names>J</given-names></name><name><surname>Saiki</surname><given-names>I</given-names></name><name><surname>Nojima</surname><given-names>H</given-names></name><name><surname>Kuraishi</surname><given-names>Y</given-names></name></person-group><article-title>Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation</article-title><source>Eur J Pharmacol</source><volume>441</volume><fpage>185</fpage><lpage>191</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0014-2999(02)01450-4</pub-id><pub-id pub-id-type="pmid">12063091</pub-id></element-citation></ref>
<ref id="b29-ol-0-0-7870"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ash</surname><given-names>SA</given-names></name><name><surname>Buggy</surname><given-names>DJ</given-names></name></person-group><article-title>Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence</article-title><source>Best Pract Res Clin Anaesthesiol</source><volume>27</volume><fpage>441</fpage><lpage>456</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.bpa.2013.10.005</pub-id><pub-id pub-id-type="pmid">24267550</pub-id></element-citation></ref>
<ref id="b30-ol-0-0-7870"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Kshirsagar</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Schwartz</surname><given-names>R</given-names></name><name><surname>Law</surname><given-names>PY</given-names></name><name><surname>Yee</surname><given-names>D</given-names></name><name><surname>Hebbel</surname><given-names>RP</given-names></name></person-group><article-title>Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth</article-title><source>Cancer Res</source><volume>62</volume><fpage>4491</fpage><lpage>4498</lpage><year>2002</year><pub-id pub-id-type="pmid">12154060</pub-id></element-citation></ref>
<ref id="b31-ol-0-0-7870"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>LH</given-names></name><name><surname>Li</surname><given-names>HT</given-names></name><name><surname>Lin</surname><given-names>WQ</given-names></name><name><surname>Tan</surname><given-names>HY</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>ZJ</given-names></name><name><surname>Zhou</surname><given-names>JH</given-names></name></person-group><article-title>Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts</article-title><source>Sci Rep</source><volume>6</volume><fpage>18706</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep18706</pub-id><pub-id pub-id-type="pmid">26729257</pub-id></element-citation></ref>
<ref id="b32-ol-0-0-7870"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahaman</surname><given-names>SO</given-names></name><name><surname>Vogelbaum</surname><given-names>MA</given-names></name><name><surname>Haque</surname><given-names>SJ</given-names></name></person-group><article-title>Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: Involvement of IL-13Ralpha2</article-title><source>Cancer Res</source><volume>65</volume><fpage>2956</fpage><lpage>2963</lpage><year>2005</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3592</pub-id><pub-id pub-id-type="pmid">15805299</pub-id></element-citation></ref>
<ref id="b33-ol-0-0-7870"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamprecht</surname><given-names>B</given-names></name><name><surname>Kreher</surname><given-names>S</given-names></name><name><surname>Anagnostopoulos</surname><given-names>I</given-names></name><name><surname>J&#x00F6;hrens</surname><given-names>K</given-names></name><name><surname>Monteleone</surname><given-names>G</given-names></name><name><surname>Jundt</surname><given-names>F</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Janz</surname><given-names>M</given-names></name><name><surname>D&#x00F6;rken</surname><given-names>B</given-names></name><name><surname>Mathas</surname><given-names>S</given-names></name></person-group><article-title>Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha</article-title><source>Blood</source><volume>112</volume><fpage>3339</fpage><lpage>3347</lpage><year>2008</year><pub-id pub-id-type="doi">10.1182/blood-2008-01-134783</pub-id><pub-id pub-id-type="pmid">18684866</pub-id></element-citation></ref>
<ref id="b34-ol-0-0-7870"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Paladino</surname><given-names>D</given-names></name><name><surname>Sengupta</surname><given-names>B</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Holloway</surname><given-names>RW</given-names></name><name><surname>Ingersoll</surname><given-names>SB</given-names></name><name><surname>Turkson</surname><given-names>J</given-names></name></person-group><article-title>Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells</article-title><source>Oncogene</source><volume>31</volume><fpage>2309</fpage><lpage>2322</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/onc.2011.409</pub-id><pub-id pub-id-type="pmid">21909139</pub-id></element-citation></ref>
<ref id="b35-ol-0-0-7870"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sordella</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name></person-group><article-title>Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</article-title><source>Science</source><volume>305</volume><fpage>1163</fpage><lpage>1167</lpage><year>2004</year><pub-id pub-id-type="doi">10.1126/science.1101637</pub-id><pub-id pub-id-type="pmid">15284455</pub-id></element-citation></ref>
<ref id="b36-ol-0-0-7870"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Rodriguez</surname><given-names>AA</given-names></name><name><surname>Elvin</surname><given-names>JA</given-names></name><name><surname>Vergilio</surname><given-names>JA</given-names></name><name><surname>Suh</surname><given-names>JH</given-names></name><name><surname>Chumsri</surname><given-names>S</given-names></name><name><surname>Morosini</surname><given-names>D</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name><etal/></person-group><article-title>Abstract P6-03-02: EGFR genomic alterations in 5,605 cases of refractory and metastatic breast cancer</article-title><source>Cancer Res</source><volume>76</volume><supplement>Suppl 4</supplement><fpage>P6</fpage><lpage>03-02</lpage><year>2016</year><pub-id pub-id-type="doi">10.1158/1538-7445.SABCS15-P6-03-02</pub-id></element-citation></ref>
<ref id="b37-ol-0-0-7870"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milagre</surname><given-names>CS</given-names></name><name><surname>Gopinathan</surname><given-names>G</given-names></name><name><surname>Everitt</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>RG</given-names></name><name><surname>Kulbe</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Hollingsworth</surname><given-names>RE</given-names></name><name><surname>Grose</surname><given-names>R</given-names></name><name><surname>Bowtell</surname><given-names>DD</given-names></name><name><surname>Hochhauser</surname><given-names>D</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name></person-group><article-title>Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer</article-title><source>Cancer Res</source><volume>75</volume><fpage>1255</fpage><lpage>1264</lpage><year>2015</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1801</pub-id><pub-id pub-id-type="pmid">25670170</pub-id></element-citation></ref>
<ref id="b38-ol-0-0-7870"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falchook</surname><given-names>GS</given-names></name><name><surname>Naing</surname><given-names>A</given-names></name><name><surname>Wheler</surname><given-names>JJ</given-names></name><name><surname>Tsimberidou</surname><given-names>AM</given-names></name><name><surname>Zinner</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>DS</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Piha-Paul</surname><given-names>SA</given-names></name><name><surname>Janku</surname><given-names>F</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer</article-title><source>Oncoscience</source><volume>1</volume><fpage>540</fpage><lpage>549</lpage><year>2014</year><pub-id pub-id-type="doi">10.18632/oncoscience.73</pub-id><pub-id pub-id-type="pmid">25594061</pub-id></element-citation></ref>
<ref id="b39-ol-0-0-7870"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engilbertsson</surname><given-names>H</given-names></name><name><surname>Aaltonen</surname><given-names>KE</given-names></name><name><surname>Bj&#x00F6;rnsson</surname><given-names>S</given-names></name><name><surname>Kristmundsson</surname><given-names>T</given-names></name><name><surname>Patschan</surname><given-names>O</given-names></name><name><surname>Ryd&#x00E9;n</surname><given-names>L</given-names></name><name><surname>Gudjonsson</surname><given-names>S</given-names></name></person-group><article-title>Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream</article-title><source>J Urol</source><volume>193</volume><fpage>53</fpage><lpage>57</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.juro.2014.06.083</pub-id><pub-id pub-id-type="pmid">24996129</pub-id></element-citation></ref>
<ref id="b40-ol-0-0-7870"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>JN</given-names></name><name><surname>Tan</surname><given-names>XY</given-names></name></person-group><article-title>Vaccination with xenogeneic tumor endothelial proteins isolated <italic>in situ</italic> inhibits tumor angiogenesis and spontaneous metastasis</article-title><source>Int J Cancer</source><volume>125</volume><fpage>124</fpage><lpage>132</lpage><year>2009</year><pub-id pub-id-type="doi">10.1002/ijc.24362</pub-id><pub-id pub-id-type="pmid">19350628</pub-id></element-citation></ref>
<ref id="b41-ol-0-0-7870"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram&#x00ED;rez</surname><given-names>MF</given-names></name><name><surname>Huitink</surname><given-names>JM</given-names></name><name><surname>Cata</surname><given-names>JP</given-names></name></person-group><article-title>Perioperative clinical interventions that modify the immune response in cancer patients</article-title><source>Open J Anesthesiology</source><volume>3</volume><fpage>133</fpage><lpage>139</lpage><year>2013</year><pub-id pub-id-type="doi">10.4236/ojanes.2013.33031</pub-id></element-citation></ref>
<ref id="b42-ol-0-0-7870"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Mo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer</article-title><source>J Surg Oncol</source><volume>102</volume><fpage>325</fpage><lpage>330</lpage><year>2010</year><pub-id pub-id-type="doi">10.1002/jso.21644</pub-id><pub-id pub-id-type="pmid">20589712</pub-id></element-citation></ref>
<ref id="b43-ol-0-0-7870"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavira</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Assaf</surname><given-names>SA</given-names></name><name><surname>Ingles</surname><given-names>SA</given-names></name><name><surname>Llanes</surname><given-names>A</given-names></name><name><surname>Chmait</surname><given-names>R</given-names></name></person-group><article-title>Anti-angiogenic state in twin-twin transfusion syndrome ameliorated after laser surgery</article-title><source>Ame J Obst Gynecology</source><volume>206</volume><fpage>S52</fpage><lpage>S52</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ajog.2011.10.874</pub-id></element-citation></ref>
<ref id="b44-ol-0-0-7870"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zielinski</surname><given-names>CE</given-names></name><name><surname>Mele</surname><given-names>F</given-names></name><name><surname>Aschenbrenner</surname><given-names>D</given-names></name><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Ronchi</surname><given-names>F</given-names></name><name><surname>Gattorno</surname><given-names>M</given-names></name><name><surname>Monticelli</surname><given-names>S</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><article-title>Pathogen-induced human TH17 cells produce IFN-&#x03B3; or IL-10 and are regulated by IL-1&#x03B2;</article-title><source>Nature</source><volume>484</volume><fpage>514</fpage><lpage>518</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/nature10957</pub-id><pub-id pub-id-type="pmid">22466287</pub-id></element-citation></ref>
<ref id="b45-ol-0-0-7870"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x0027;Connell</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>MW</given-names></name><name><surname>O&#x0027;Sullivan</surname><given-names>GC</given-names></name><name><surname>Collins</surname><given-names>JK</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name></person-group><article-title>The Fas counterattack: Cancer as a site of immune privilege</article-title><source>Immunol Today</source><volume>20</volume><fpage>46</fpage><lpage>52</lpage><year>1999</year><pub-id pub-id-type="doi">10.1016/S0167-5699(98)01382-6</pub-id><pub-id pub-id-type="pmid">10081230</pub-id></element-citation></ref>
<ref id="b46-ol-0-0-7870"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x00FC;ller</surname><given-names>CB</given-names></name><name><surname>De Bastiani</surname><given-names>MA</given-names></name><name><surname>Becker</surname><given-names>M</given-names></name><name><surname>Fran&#x00E7;a</surname><given-names>FS</given-names></name><name><surname>Branco</surname><given-names>MA</given-names></name><name><surname>Castro</surname><given-names>MA</given-names></name><name><surname>Klamt</surname><given-names>F</given-names></name></person-group><article-title>Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancer</article-title><source>Oncotarget</source><volume>6</volume><fpage>3531</fpage><lpage>3539</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.3471</pub-id><pub-id pub-id-type="pmid">25784483</pub-id></element-citation></ref>
<ref id="b47-ol-0-0-7870"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>SP</given-names></name><name><surname>Mark</surname><given-names>KG</given-names></name><name><surname>Leslie</surname><given-names>K</given-names></name><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Motoi</surname><given-names>N</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Travis</surname><given-names>WD</given-names></name><name><surname>Bornmann</surname><given-names>W</given-names></name><name><surname>Veach</surname><given-names>D</given-names></name><name><surname>Clarkson</surname><given-names>B</given-names></name><name><surname>Bromberg</surname><given-names>JF</given-names></name></person-group><article-title>Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</article-title><source>J Clin Invest</source><volume>117</volume><fpage>3846</fpage><lpage>3856</lpage><year>2007</year><pub-id pub-id-type="doi">10.1172/JCI31871</pub-id><pub-id pub-id-type="pmid">18060032</pub-id></element-citation></ref>
<ref id="b48-ol-0-0-7870"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>BD</given-names></name><name><surname>Buckalew</surname><given-names>AR</given-names></name><name><surname>DeVito</surname><given-names>MJ</given-names></name><name><surname>Ross</surname><given-names>D</given-names></name><name><surname>Bryant</surname><given-names>PL</given-names></name><name><surname>Schmid</surname><given-names>JE</given-names></name></person-group><article-title>EGF and TGF-alpha expression influence the developmental toxicity of TCDD: Dose response and AhR phenotype in EGF, TGF-alpha, and EGF &#x002B; TGF-alpha knockout mice</article-title><source>Toxicol Sci</source><volume>71</volume><fpage>84</fpage><lpage>95</lpage><year>2003</year><pub-id pub-id-type="doi">10.1093/toxsci/71.1.84</pub-id><pub-id pub-id-type="pmid">12520078</pub-id></element-citation></ref>
<ref id="b49-ol-0-0-7870"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>CT</given-names></name><name><surname>Harrington</surname><given-names>LE</given-names></name><name><surname>Mangan</surname><given-names>PR</given-names></name><name><surname>Gavrieli</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><article-title>Thl7: An effector CD4 T cell lineage with regulatory T cell ties</article-title><source>Immunity</source><volume>24</volume><fpage>677</fpage><lpage>688</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.immuni.2006.06.002</pub-id><pub-id pub-id-type="pmid">16782025</pub-id></element-citation></ref>
<ref id="b50-ol-0-0-7870"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>B</given-names></name><name><surname>Saigal</surname><given-names>B</given-names></name><name><surname>Parikh</surname><given-names>N</given-names></name><name><surname>Gallick</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>FM</given-names></name></person-group><article-title>Sustained src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding</article-title><source>Cancer Res</source><volume>69</volume><fpage>1958</fpage><lpage>1965</lpage><year>2009</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2944</pub-id><pub-id pub-id-type="pmid">19223541</pub-id></element-citation></ref>
<ref id="b51-ol-0-0-7870"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juergens</surname><given-names>RA</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name></person-group><article-title>Adjuvant treatment in non-small cell lung cancer: Where are we now?</article-title><source>J Natl Compr Canc Netw</source><volume>4</volume><fpage>595</fpage><lpage>600</lpage><year>2006</year><pub-id pub-id-type="doi">10.6004/jnccn.2006.0049</pub-id><pub-id pub-id-type="pmid">16813727</pub-id></element-citation></ref>
<ref id="b52-ol-0-0-7870"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Glynn</surname><given-names>TJ</given-names></name></person-group><article-title>Epidemiology of lung cancer</article-title><source>Radiol Clin North Am</source><volume>38</volume><fpage>453</fpage><lpage>470</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0033-8389(05)70176-7</pub-id><pub-id pub-id-type="pmid">10855253</pub-id></element-citation></ref>
<ref id="b53-ol-0-0-7870"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fossella</surname><given-names>FV</given-names></name><name><surname>DeVore</surname><given-names>R</given-names></name><name><surname>Kerr</surname><given-names>RN</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><name><surname>Natale</surname><given-names>RR</given-names></name><name><surname>Dunphy</surname><given-names>F</given-names></name><name><surname>Kalman</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group</article-title><source>J Clin Oncol</source><volume>18</volume><fpage>2354</fpage><lpage>2362</lpage><year>2000</year><pub-id pub-id-type="doi">10.1200/JCO.2000.18.12.2354</pub-id><pub-id pub-id-type="pmid">10856094</pub-id></element-citation></ref>
<ref id="b54-ol-0-0-7870"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>B</given-names></name><name><surname>van Dinther</surname><given-names>M</given-names></name><name><surname>Ten Dijke</surname><given-names>P</given-names></name><name><surname>Inman</surname><given-names>GJ</given-names></name></person-group><article-title>Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation</article-title><source>Cancer Res</source><volume>69</volume><fpage>9254</fpage><lpage>9262</lpage><year>2009</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2912</pub-id><pub-id pub-id-type="pmid">19996292</pub-id></element-citation></ref>
<ref id="b55-ol-0-0-7870"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>GW</given-names></name><name><surname>Shah</surname><given-names>SR</given-names></name></person-group><article-title>Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer</article-title><source>Pharmacotherapy</source><volume>28</volume><fpage>742</fpage><lpage>754</lpage><year>2008</year><pub-id pub-id-type="doi">10.1592/phco.28.6.742</pub-id><pub-id pub-id-type="pmid">18503402</pub-id></element-citation></ref>
<ref id="b56-ol-0-0-7870"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siveen</surname><given-names>KS</given-names></name><name><surname>Sikka</surname><given-names>S</given-names></name><name><surname>Surana</surname><given-names>R</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>AP</given-names></name><name><surname>Tan</surname><given-names>BK</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Bishayee</surname><given-names>A</given-names></name></person-group><article-title>Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors</article-title><source>Biochim Biophys Acta</source><volume>1845</volume><fpage>136</fpage><lpage>154</lpage><year>2014</year><pub-id pub-id-type="pmid">24388873</pub-id></element-citation></ref>
<ref id="b57-ol-0-0-7870"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>JI</given-names></name><name><surname>Grandis</surname><given-names>JR</given-names></name></person-group><article-title>STAT signaling in head and neck cancer</article-title><source>Oncogene</source><volume>19</volume><fpage>2489</fpage><lpage>2495</lpage><year>2000</year><pub-id pub-id-type="doi">10.1038/sj.onc.1203483</pub-id><pub-id pub-id-type="pmid">10851047</pub-id></element-citation></ref>
<ref id="b58-ol-0-0-7870"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morlacchi</surname><given-names>P</given-names></name><name><surname>Robertson</surname><given-names>FM</given-names></name><name><surname>Klostergaard</surname><given-names>J</given-names></name><name><surname>McMurray</surname><given-names>JS</given-names></name></person-group><article-title>Targeting SH2 domains in breast cancer</article-title><source>Future Med Chem</source><volume>6</volume><fpage>1909</fpage><lpage>1926</lpage><year>2014</year><pub-id pub-id-type="doi">10.4155/fmc.14.120</pub-id><pub-id pub-id-type="pmid">25495984</pub-id></element-citation></ref>
<ref id="b59-ol-0-0-7870"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapeire</surname><given-names>L</given-names></name><name><surname>Hendrix</surname><given-names>A</given-names></name><name><surname>Lambein</surname><given-names>K</given-names></name><name><surname>Van Bockstal</surname><given-names>M</given-names></name><name><surname>Braems</surname><given-names>G</given-names></name><name><surname>Van Den Broecke</surname><given-names>R</given-names></name><name><surname>Limame</surname><given-names>R</given-names></name><name><surname>Mestdagh</surname><given-names>P</given-names></name><name><surname>Vandesompele</surname><given-names>J</given-names></name><name><surname>Vanhove</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling</article-title><source>Cancer Res</source><volume>74</volume><fpage>6806</fpage><lpage>6819</lpage><year>2014</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0160</pub-id><pub-id pub-id-type="pmid">25252914</pub-id></element-citation></ref>
<ref id="b60-ol-0-0-7870"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penuel</surname><given-names>E</given-names></name><name><surname>Kapp</surname><given-names>AV</given-names></name><name><surname>Do</surname><given-names>A</given-names></name><name><surname>Tam</surname><given-names>R</given-names></name><name><surname>Sumiyoshi</surname><given-names>T</given-names></name><name><surname>Marathe</surname><given-names>C</given-names></name><name><surname>Sa</surname><given-names>S</given-names></name><name><surname>Peale</surname><given-names>F</given-names></name><name><surname>Lackner</surname><given-names>M</given-names></name><name><surname>Holden</surname><given-names>S</given-names></name><etal/></person-group><article-title>Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in &#x2265;2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]</article-title><source>Cancer Res</source><volume>75</volume><supplement>Suppl 15</supplement><fpage>1553</fpage><year>2015</year><pub-id pub-id-type="doi">10.1158/1538-7445.AM2015-1553</pub-id></element-citation></ref>
<ref id="b61-ol-0-0-7870"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luwor</surname><given-names>RB</given-names></name><name><surname>Baradaran</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>LE</given-names></name><name><surname>Iaria</surname><given-names>J</given-names></name><name><surname>Nheu</surname><given-names>TV</given-names></name><name><surname>Amiry</surname><given-names>N</given-names></name><name><surname>Hovens</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Kaye</surname><given-names>AH</given-names></name><name><surname>Zhu</surname><given-names>HJ</given-names></name></person-group><article-title>Targeting Stat3 and Smad7 to restore TGF-&#x03B2; cytostatic regulation of tumor cells <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Oncogene</source><volume>32</volume><fpage>2433</fpage><lpage>2441</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/onc.2012.260</pub-id><pub-id pub-id-type="pmid">22751114</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-0-0-7870" position="float">
<label>Figure 1.</label>
<caption><p>The numbers of the lung metastasis nodes were observed and imaged using a camera after fixing with Bouin&#x0027;s solution.</p></caption>
<graphic xlink:href="ol-15-04-4662-g00.tif"/>
</fig>
<fig id="f2-ol-0-0-7870" position="float">
<label>Figure 2.</label>
<caption><p>Changes in cytokine concentration in serum of rats that underwent different treatments. The changes in (A) IFN-&#x03B3;, (B) TGF-&#x03B1; and (C) VEGF concentration in tumor-bearing rats in groups C, G and G &#x002B; E. &#x002A;P&#x003C;0.05. IFN-&#x03B3;, interferon-&#x03B3;; TGF-&#x03B1;, transforming growth factor-&#x03B1;; VEGF, vascular endothelial growth factor; group C, rats that did not undergo hepatectomy; group G &#x002B; E, rats that underwent hepatectomy under general anesthetic with epidural block; group G, rats that underwent hepatectomy under general anesthetic.</p></caption>
<graphic xlink:href="ol-15-04-4662-g01.tif"/>
</fig>
<fig id="f3-ol-0-0-7870" position="float">
<label>Figure 3.</label>
<caption><p>Western blot analysis. Levels of p-STAT3 and p-EGFR in tumor-bearing rats treated with and without GA and GEA. &#x002A;P&#x003C;0.05. p-STAT3, phosphorylated signal transducer and activator of transcription 3; EGFR, epidermal growth factor receptor; group C, rats that did not undergo hepatectomy; group G &#x002B; E, rats that underwent hepatectomy under general anesthetic with epidural block; group G, rats that underwent hepatectomy under general anesthetic.</p></caption>
<graphic xlink:href="ol-15-04-4662-g02.tif"/>
</fig>
<table-wrap id="tI-ol-0-0-7870" position="float">
<label>Table I.</label>
<caption><p>Quantified data of metastases analysis (n=10).</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Groups</th>
<th align="center" valign="bottom">Lung metastases<sup><xref rid="tfn1-ol-0-0-7870" ref-type="table-fn">a</xref></sup>, n</th>
<th align="center" valign="bottom">Abdominal lymph node metastasis, n</th>
<th align="center" valign="bottom">Rate of malignant ascites, n</th>
<th align="center" valign="bottom">Abdominal wall-implanted nodules, n</th>
<th align="center" valign="bottom">Volumes of lung with all metastases<sup><xref rid="tfn1-ol-0-0-7870" ref-type="table-fn">a</xref></sup>, cm<sup>3</sup></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Group C</td>
<td char="&#x00B1;" align="char" valign="top">40&#x00B1;6</td>
<td align="center" valign="top">7/10</td>
<td align="center" valign="top">8/10</td>
<td align="center" valign="top">8/10</td>
<td char="&#x00B1;" align="char" valign="top">14.85&#x00B1;1.66</td>
</tr>
<tr>
<td align="left" valign="top">Group G &#x002B; E</td>
<td char="&#x00B1;" align="char" valign="top">18&#x00B1;6<sup><xref rid="tfn2-ol-0-0-7870" ref-type="table-fn">b</xref>,<xref rid="tfn3-ol-0-0-7870" ref-type="table-fn">c</xref></sup></td>
<td align="center" valign="top">1/10<sup><xref rid="tfn2-ol-0-0-7870" ref-type="table-fn">b</xref>,<xref rid="tfn3-ol-0-0-7870" ref-type="table-fn">c</xref></sup></td>
<td align="center" valign="top">2/10<sup><xref rid="tfn2-ol-0-0-7870" ref-type="table-fn">b</xref>,<xref rid="tfn3-ol-0-0-7870" ref-type="table-fn">c</xref></sup></td>
<td align="center" valign="top">2/10<sup><xref rid="tfn2-ol-0-0-7870" ref-type="table-fn">b</xref>,<xref rid="tfn3-ol-0-0-7870" ref-type="table-fn">c</xref></sup></td>
<td char="&#x00B1;" align="char" valign="top">12.93&#x00B1;1.52</td>
</tr>
<tr>
<td align="left" valign="top">Group G</td>
<td char="&#x00B1;" align="char" valign="top">38&#x00B1;5</td>
<td align="center" valign="top">6/10</td>
<td align="center" valign="top">7/10</td>
<td align="center" valign="top">5/10</td>
<td char="&#x00B1;" align="char" valign="top">13.06&#x00B1;2.08</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ol-0-0-7870"><label>a</label><p>Mean &#x00B1; standard deviation.</p></fn>
<fn id="tfn2-ol-0-0-7870"><label>b</label><p>P&#x003C;0.05 vs. group G</p></fn>
<fn id="tfn3-ol-0-0-7870"><label>c</label><p>P&#x003C;0.05 vs. group C. Group C, rats that did not undergo hepatectomy; group G &#x002B; E, rats that underwent hepatectomy under general anesthetic with epidural block; group G, rats that underwent hepatectomy under general anesthetic.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
